Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

OBJECTIVE: We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). DESIGN: Phase II and III, multicenter, open-label, randomized controlled trials. METHODS: 108 and 343 children with treat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Endocrinol
Asıl Yazarlar: Luo, Xiaoping, Hou, Ling, Liang, Li, Dong, Guanping, Shen, Shuixian, Zhao, Zhuhui, Gong, Chun Xiu, Li, Yuchuan, Du, Min-lian, Su, Zhe, Du, Hongwei, Yan, Chaoying
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Bioscientifica Ltd 2017
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488390/
https://ncbi.nlm.nih.gov/pubmed/28566441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-16-0905
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller